The Antitumor Activity of the Somatostatin Structural Derivative (TT-232) on Different Human Tumor Xenografts

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 4061-4066

  Tejeda, Miguel ^a   Gaal, D ^a   Barna, K ^a   Csuka, O ^a   Keri Gy ^b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Human tumor xenograft; New somatostatin analog; TT 232; Tumor therapy

Indexed keywords

DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLCYSTEINYLTHREONINAMIDE 2,6 DISULFIDE; SOMATOSTATIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CARCINOMA; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HT29 CELLS; HUMANS; MALE; MELANOMA; PEPTIDES, CYCLIC; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0344874041     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Reichlin S: Somatostatin. Engl J Med 309: 1495-1501, 1983.
2. Brazeau P, Vale W and Burgus R: Hypothalmic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77-79, 1973.
3. Robbins RJ: Somatostatin and cancer. Metabolism 45: 95-100, 1996.
4. Kéri Gy, Mezo I, Horvath A, Vadasz Zs, Balogh A, Idei M, Vantus T, Teplan I, Mak M, Horvath J, Pal K and Csuka O: Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. Biochem Biophy Res Comm 191: 681-687, 1983.
5. Kéri Gy, Érchegyi J, Horvath A, Mezo I, Vantus T, Balogh A, Vadasz Zs, Bököny Gy, Seprodi J, Teplan I, Csuka O, Tejeda M, Gaal D, Szegedi Zs, Szende B, Roze C, Kaalthoff H and Ulrich A: A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci 93: 12513-12518, 1996.
6. Diaconu CC, Szatmari M, Kéri Gy and Venetianer A: Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Brit Canc 80(8): 1197-1203, 1999.
7. Vantus T, Kéri Gy, Krivicskiene T, Valius M, Steták A, Keppens S, Csermely P, Bauer PI, Bökönyi Gy, Declercq W, Vandenabeele P, Merlevede W and Vandenheede JR: The somatostatin analogue TT-232 induces apoptosis in A431 cells. Sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinases. Cellular Signalling 13(10): 717-725, 2001.
8. Steták A, Lankenau A, Vantus T, Csermely P, Ullrich A and Kéri Gy: The antitumor somatostatin analogue TT-232 induced cell cycle arrest through PKC and c-Scr. Biochem Biophys Res Comm 285(2): 483-488, 2001.
9. Stetak A, Csermely P, Ullrich A and Kéri Gy: Physical and functional interactions between protein tyrosine phosphatase α, PKCδ and P1 3-kinase, and PKC. Biochem Biophys Res Comm 288: 564-572, 2001.
10. Vantus T, Csermely P, Mezo I, Teplan I and Kéri Gy: Somatostatin analogue TT-232 induces biphasic activation of phosphotyrosine phosphatase in human colon tumor cell lines SW-620. Tumor Biol 16: 261-267, 1995.
11. Tovari J, Szende B, Bocsi J, Falaschi A, Simoncsits A, Pongor S, Érchegyi J, Stetak A and Kéri Gy: A somatostatin analogue induces translocation of KU-86 autoantigen from the cytosol to the nucleus in colon tumour cell. Cell Signalling 10(4): 277-282, 1998.
12. Schwab R, Froidevaux S, Paku S, Tejeda M, Szende B, Pap A, Belinger Ch, Eberle A and Kéri Gy: Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumors. Anticancer Res 21: 71-76, 2001.
13. Tejeda M, Gaal D, Schwab R, Pap A and Kéri Gy: In vivo antitumor activity of TT-232 a novel somatostatin analog. Anticancer Res 19: 3265-3268, 1999.
14. Tejeda M, Gaal D, Kéri Gy, Schwab R and Pap A: Influence of various administration route on the antitumor efficacy of TT-232, a novel somatostatin analog. Anticancer Res 20: 1023-1027, 2000.
15. Tejeda M, Gaal D and Kéri Gy: Influence of various administration routes on the antitumor activity of a somatostatin analogue, TT-232. Canc Detect Prevent 26(1): 44-45, 2002.
16. Tejeda M, Gaal D, Csuka O, Ullrich A, Schwab R, Pap A, Horvath A and Kéri Gy: The antitumor effect of the somatostatin analogue TT-232 depends on the treatment regimen. Canc Detect Protect 27(2): 155-162, 2003.
17. Szende B, Horvath A, Bökönyi Gy and Kéri Gy: Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. Brit Canc 88(1): 132-136, 2003.
18. Alza Technical Information Manual: Alza Corporation 2: 2-28, 1994.
19. Fara JM: Osmotic delivery systems for research. Methods Enzymol 112: 470-484, 1995.